We are hiring a Software Engineer, in Melbourne, Australia! If you’re a software engineer who enjoys hands‑on development, working closely with hardware, and building technology that genuinely impacts healthcare, this could be your next move. For more information apply here: https://lnkd.in/gvfnBhz8
Invetech
Engineering Services
San Diego, California 17,400 followers
From complex automation to CGT scale-up, we help turn ambition into production via design, engineering & manufacturing.
About us
Invetech is a global engineering and manufacturing partner for diagnostics, IVD, cell and gene therapy, and medtech companies. We help pharmaceutical, biotech, diagnostics and healthcare organisations design, develop, automate and manufacture products and GMP-ready production systems. From concept through to commercial production, we bring together product design and development, automation, robotics, software, system integration, industrialisation, tech transfer and contract manufacturing to turn complex science into scalable, reliable solutions. In diagnostics, we develop and industrialise instruments, consumables, and point-of-care or benchtop systems for robust performance at scale. In cell and gene therapy, we design GMP-ready automated manufacturing systems and related consumables that improve consistency, throughput and process control. In medtech, we support complex devices and combination products with a strong focus on manufacturability, validation and commercial transfer. With teams in San Diego and in Melbourne, Invetech supports customers across the United States and Australia with engineering, manufacturing and scale-up expertise. By combining design, automation and manufacturing in one partner, we help reduce risk, accelerate timelines and improve readiness for commercialisation. We are FDA Registered (3005269352), ISO13485, ISO9001 & ISO 7 (Class 10,000) Cleanroom Certified. Contact us to discuss diagnostics development, cell therapy automation, medtech engineering and contract manufacturing.
- Website
-
https://www.invetechgroup.com
External link for Invetech
- Industry
- Engineering Services
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Founded
- 1987
- Specialties
- Product Innovation, Full-Spectrum Product Realization, Cell Therapy End-to End Automation, Contract Manufacturing, Lifecycle Management, Product Development , Cell and Gene Therapy, Automation, Process scale up, Engineering, Design for manufacturing (DFM), Automation and robotics, Lab automation, Validation and verification, Cost optimisation, VAVE, Manufacturing scale-up, Medtech engineering, Diagnostics development, diagnostic instruments, CGT automation, GMP Manufacturing, Systems integration, Medical device development, Closed system design, Product lifecycle, IVD Instrument development, Manufacturing automation, Software engineering, Instrument engineering, Life sciences automation, Single use sets, Manufacturing, Clean room, ISO 13485, ISO 9001, FDA registered manufacturing, and ISO 7
Locations
-
Primary
Get directions
6740 Cobra Way STE 200
San Diego, California 92121, US
-
Get directions
495 Blackburn Road
Melbourne, Victoria 3149, AU
Employees at Invetech
Updates
-
Congratulations to MeMed on achieving FDA Breakthrough Device Designation for the #MeMedBVFlex™ Capillary Blood Technology and thank you to MeMed's Co-founder and CEO Eran Eden, for the shoutout. We’re proud to have collaborated with your team on the product development of a flexible instrument that enables the transition from whole blood to capillary samples without requiring hardware or software changes. This milestone highlights MeMed’s smart approach to innovation turning advanced science into practical diagnostic solutions that can make a meaningful difference in clinical care.
Thrilled to share that FDA just granted Breakthrough Device Designation to our #MeMedBVFlex™ Capillary Blood Technology! To receive Breakthrough status, we had to demonstrate to the FDA that our technology addresses life-threatening conditions and has the potential to significantly improve the standard of care. MeMed BV Flex is designed to do just that - distinguish between bacterial and viral infections based on the body’s immune response, from just a few drops of blood. This is critical, especially for vulnerable populations like young children and the elderly, where access to blood is limited. It’s also designed to be very simple to operate, a key hurdle for real-world adoption. Once cleared and CLIA-wavied, it’s intended for use in both hospitals and decentralized settings. To get here, we had to solve some tough technological challenges: measuring multiple proteins at laboratory-grade performance from just a few drops of blood, in minutes, and then integrating that data with machine learning at the point-of-care. It took us years of focused development and validation, with incredible team members and partners. The Breakthrough designation will help streamline our path toward regulatory clearance and support future reimbursement efforts with our partners, ultimately advancing care for patients with #fever and #sepsis. Deeply grateful to the FDA for the recognition. Deeply proud of the relentless #MeMed team for continuing to push technology beyond what’s considered “reasonable.” Improving the standard of care requires technologies that may seem “unreasonable”, at least at first 😉 Oh… and stating the obvious: now that the core technology is established, it can be expanded to many other conditions... work in progress. For more details see: https://lnkd.in/daGAvFB4 *MeMed BV Flex™ is an investigational device and has not been approved or cleared for sale by any regulatory authority. #MeMed #FDA #BreakthroughDevice #HostResponse #Diagnostics #ML #BloodDrop
-
We’re hiring a People & Culture Business Partner in Melbourne, Australia. If you’re a pragmatic, people‑focused professional who enjoys variety and impact, we’d love to hear from you. For more information apply here: https://lnkd.in/gQwxSTuQ
-
We are hiring a Digital Marketing Manager on the East Coast, US or in Australia! If you’re a hands-on digital marketer who loves autonomy, experimentation and building things that matter, this could be your next move. For more information apply here: https://lnkd.in/gMviB4yk
-
We were pleased to welcome the SMART CRC team to Invetech for a site visit. It was great to host such engaging discussions on manufacturability and scale up. The session reinforced the value of early collaboration between academia, researchers, and industry, something SMART CRC facilitates so effectively. The visit also provided an opportunity to share how Invetech supports the translation of cell and gene therapies by bringing together engineering, automation, and manufacturing expertise, and to explore how we can work together to help accelerate progress. Simon Cool, Isaac J Coonan, Sarah Costanzo, Andreas Knaack, Ewa Douroux, Richard Badham
-
-
Today, Andreas Knaack represented Invetech at the SMART CRC showcase. Andreas presented and joined a panel discussion with Dr Julien Freitag, Tara Cassidy & Simon Cool. In regenerative health and advanced manufacturing, progress depends on being able to bridge the gap between promising science and scalable, manufacturable, and commercially viable products. That is where Invetech is focused. We turn complex ideas into practical systems that enable the scale-up to high patient volumes. We were pleased to be part of today’s conversation and look forward to connecting with others working to strengthen the regenerative medicine ecosystem. A big thanks to SMART CRC for fostering great collaborations that drive forward solutions for advanced therapies manufacturing. #SMARTCRC #RegenerativeMedicine #AdvancedManufacturing #Biotech #Invetech
-
-
We’re excited to share that Trenchant Bio and Invetech Group have completed a strategic alliance to develop a fully automated cell & gene therapy manufacturing solution. Cell and gene therapies are transforming what’s possible for patients, but manufacturing remains the bottleneck: complex workflows, high labour intensity, variability and long turnaround times. This is exactly the kind of challenge Invetech is built for, solving the hardest, most complex problems at the intersection of science, engineering, and scalable manufacturing. By combining Invetech’s and Trenchant’s visions, we’re working toward a solution designed to materially improve speed, consistency, and scalability, so advanced therapies can reach more people. For more details, see: https://lnkd.in/gU78XN-v #CellAndGeneTherapy #Automation #AdvancedTherapies #Engineering
-
We’re proud to congratulate Janet O'Meara on her appointment to the BioMelbourne Network. Janet is Invetech’s CFO and is widely respected for her board level leadership, strategic insight, and collaborative approach. Her appointment is a testament to her deep experience and ongoing contribution to the health and life sciences sector, and we’re delighted to see her bring this expertise to the BioMelbourne Network. Reflecting on the role, Janet shared: "I am honoured to share my skills and experience to enhance the wonderful work of BioMelbourne Network. I see an exciting future for the health technologies industry and the opportunities it will create through continued innovation and collaboration." Congratulations, Janet. Your leadership and willingness to contribute beyond Invetech continues to make a positive impact across the industry. Read the full BioMelbourne Network announcement:
Effective March 2026, BioMelbourne Network appoints a new Chair and welcomes new Directors to its Board, strengthening governance and strategic leadership as Victoria’s peak body in the health technologies sector. The new Board Chair and Board Director appointments include: 💠 New Board Chair: Prof Vera Ignjatović AM PhD EMBA GAICD OLY Ignjatovic AM, Honorary Professor in the Department of Paediatrics at University of Melbourne, Adjunct Professor, Department of Pediatrics, Johns Hopkins University; Founder and General Manager, Ignis Innovations 💠 New Board Director: Jemimah Brennan, Director, Communications & Corporate Affairs, Moderna 💠 New Board Director: Corrina Bertram, Victorian Government Lead Partner, National Public Sector Lead Partner, Consulting, KPMG 💠 New Board Director: Janet O'Meara, Chief Financial Officer, Invetech Professor Ignjatovic succeeds Dr Emma Ball, PhD MBA GAICD, Chief Commercial Officer at INOVIQ, who is stepping down as Chair after serving on the Board for almost two years. BioMelbourne Network thanks Dr Ball for her significant contribution, guiding the organisation through a significant phase of development and reinforcing its leadership role across Victoria’s health technologies ecosystem. BioMelbourne Network also welcomes the appointment of new Board Directors Jemimah Brennan, Corrina Bertram, and Janet O’Meara. These appointments enhance the diversity of perspectives and skills at governance level, reinforcing BioMelbourne Network’s commitment to representing all key areas within the spectrum of Victoria’s ecosystem as the peak body. To learn more, view the media release here: https://buff.ly/AFwLXwC
-
-
-
-
-
+1
-
-
Today on International Women’s Day, we’re celebrating the women of Invetech. Across engineering, science, design, project leadership, software, operations, quality, marketing, finance, and HR, women bring curiosity, leadership, and diversity of thought to everything we do. They challenge assumptions, solve complex problems, and help break barriers for women in STEM—shaping Invetech’s future every single day. Through their work, leadership, and visibility, our women are helping close STEM gaps and creating clearer pathways for the next generation. #GiveToGain #IWD2026.
-
-
Big news from San Diego! We’re thrilled to introduce our new 20,000 sq ft San Diego Site—purpose‑built to accelerate next‑generation solutions across Cell & Gene Therapy, Diagnostics, and MedTech. Designed for high‑performance innovation, this state‑of‑the‑art facility brings together everything needed to move faster from idea to impact, including: • 10+ multifunctional labs supporting seamless concept‑to‑commercialization workflows • Rapid prototyping and design‑iteration capabilities to significantly shorten development timelines • ISO 13485 & ISO 9001 certified operations • ISO 7 Class cleanroom facilities This investment expands our capacity to run complex, concurrent programs. “This new site represents a major step forward in our ability to partner with clients on their most complex and ambitious programs—delivering speed, scale, and precision where it matters most.” — Andreas Knaack, President & CEO
-